Free Trial
TSE:MDNA

Medicenna Therapeutics Q2 2026 Earnings Report

Medicenna Therapeutics logo
C$0.54 -0.12 (-18.18%)
As of 09:45 AM Eastern

Medicenna Therapeutics EPS Results

Actual EPS
-C$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicenna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicenna Therapeutics Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
6:00PM ET

Earnings Documents

Medicenna Therapeutics Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Stocks in play: Medicenna Therapeutics Corp.
See More Medicenna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email.

About Medicenna Therapeutics

Medicenna Therapeutics (TSE:MDNA) Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

View Medicenna Therapeutics Profile